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February 2016 Abstracts S3Deep sequencing of circulating tumor
DNA for personalized lung cancer
detection and radiotherapy response
monitoringMaximilian Diehn Stanford University,
Stanford, CACirculating tumor DNA (ctDNA) represents a promising
biomarker for sensitive, speciﬁc, and dynamic detection
of disease burden in cancer patients. Mutations in
tumor-derived DNA represent ideal potential biomarkers
since they are highly speciﬁc to tumor cells and involved
in disease pathogenesis. However, even in advanced
cancer patients, concentrations of ctDNA are often very
low and therefore difﬁcult to detect. We have developed
a novel, ultra-sensitive and speciﬁc method for detection
of circulating tumor DNA called Cancer Personalized
Proﬁling by Deep Sequencing (CAPP-Seq). This method
was developed speciﬁcally for detection of ctDNA in non-
small cell lung cancer patients, although it is broadly
applicable to other cancer types. In this presentation I
will describe recent improvements to CAPP-Seq that
further improve the sensitivity of the assay, with a focus
on applications of ctDNA analysis in lung cancer patients
treated with radiotherapy.
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SCLC accounts for w15% of all lung cancer cases and
w220,000 deaths annually worldwide. Although
response rates to ﬁrst line platinum-based chemo-
therapy are high (w80%), progression free survival in
most patients is short (3-12 months) due to the
development of chemotherapy resistance and pro-
gressive disease. In addition, approximately 20% of
SCLC patients are classiﬁed as chemorefractory with
progressive disease within 3 months of their initial
treatment. The lack of durable chemotherapy re-
sponses contributes to the poor prognosis in SCLC;
with a 5 year survival rate of w5% (5,6). Platinum
based chemotherapy regimens have remained the same
as standard of care for SCLV for the past 30 years.
Targeted therapies have yet to make impact on patient
outcomes, although several ongoing clinical trials ofsmall molecular and immunotherapies begin to show
promise.
The majority of SCLC patients present with metastatic
disease and < 5% patients are suitable for resection
with curative intent. Biopsies of SCLC are generally
challenging, often providing a low quantity and quality of
specimen for research purposes: specimens are usually
necrotic and exhibit crush artefact. Serial biopsy in SCLC
is rare. Understanding the biology of drug resistant,
advanced and progressive disease is hampered by
limited clinical specimens to study. In SCLC, CTCs
detected by the EpCAM dependent CellSearch platform
are prevalent, CTC number is prognostic for overall and
progression free survival, the dynamic range is sufﬁcient
to use CTC number as a pharmacodynamic biomarker
and predictive CTC based biomarkers are feasible.
Marker independent CTC enrichment platforms reveal
the presence of EpCam negative SCLC CTCs. To address
the paucity of SCLC biopsies for research, we recently
developed Circulating Tumour Cell patient Derived
eXplant models in immune-compromised mice (CDX,
Hodgkinson et al, Nature Medicine, 2015).
I will describe our SCLC CDX panel derived from
chemosensitive and chemorefractory patients at baseline
and CDX matched pairs at baseline and progression. The
CDX models tested to date mirror patient responses to
standard of care chemotherapy. These models are being
exploited to search for new drugable targets, to test
targeted treatments and to interrogate treatment resis-
tance mechanisms. As few as 10 SCLC CDX cells can
recapitulate the CDX tumour suggesting a high frequency
of SCLC ‘stem-like’ cells. We also discovered that a subset
of SCLC CTCs exhibit vasculogenic mimicry, a ‘stem-like’
angiogenic switch whereby tumour cells form their own
blood vessel walls. The clinical relevance of this biology
is under investigation using CDX and xenograft models.
We hypothesize that VM facilitates dissemination, but
may also enhance drug delivery and alleviate hypoxia.
In summary, our SCLC CDX models of metastatic lung
cancer offer new avenues to study biology, mechanisms
of tumor cell dissemination.Immunotherapy in small cell lung
cancerAnna Farago Massachusetts General Hospital
Cancer Center, Boston, MASmall cell lung cancer (SCLC) is a high-grade neuroen-
docrine malignancy that accounts for approximately
15% of all lung cancers in the United States. Patients
with metastatic disease have a median survival of less
than one year, and despite a large number of early phase
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changed very little over the past 30 years.
Immunotherapy represents a new treatment paradigm
that may have clinical activity in SCLC. Multiple lines of
evidence suggest that SCLC tumors may be immuno-
genic. First, a subset of SCLCs are associated with pro-
duction of auto-antibodies or paraneoplastic syndromes,
and production of auto-antibodies predicts a higher
likelihood of complete response to ﬁrst-line chemo-
therapy and prolonged survival (Graus et al., 1997).
Second, higher ratios of circulating T effector cells to T
regulatory cells have been observed in patients with
earlier stage disease and correlate with prolonged
response to therapy (Koyama et al., 2008). Third,
although expression of programmed death ligand-1 (PD-
L1) is low on SCLC tumor cells, PD-L1 expression is
observed on tumor-inﬁltrating macrophages and is
correlated with the presence of tumor-inﬁltrating lym-
phocytes (Schultheis et al., 2015).
Clinically, SCLCs are associated with a history of sig-
niﬁcant tobacco exposure. In patients with non-small cell
lung cancer (NSCLC), response rates to inhibitors of the
immune checkpoint programmed death 1 (PD-1) recep-
tor are higher in current or former smokers compared to
never or minimal smokers. This increased response rate
is attributed to a higher mutational burden of these
carcinogen-associated tumors, leading to expression of
immunogenic neoantigens (Rizvi et al., 2015). Indeed,
SCLCs are characterized by a high somatic mutation
burden (George et al., 2015). This is likely largely
attributable to the carcinogenic effects of tobacco expo-
sure, though genomic instability may also be potentiated
by the universal loss of the tumor suppressor gene Tp53.
On the basis of these preclinical observations,
several clinical trials are now underway to assess role
of immunotherapy in SCLC. Emerging data suggest that
immune checkpoint inhibitors may have meaningful
clinical activity in this disease. CheckMate 032
(NCT01928394) is a phase 1/2 trial of nivolumab
either alone or in combination with ipilimumamb in
various tumors. Calvo et al. (ESMO, 2015) recently
presented preliminary ﬁndings from this study,
including an overall response rate of 12.7% with
nivolumab and 31.1% with nivolumab plus ipilimumab.
In a separate phase 1b study, Keynote-028
(NCT02054806), Ott et al. (ASCO, 2015) reported an
overall response rate of 35% among PD-L1 positive
SCLC patients treated with the PD-1 inhibitor pem-
brolizumab. Other inhibitors of PD-1, PD-L1 and CTLA-
4 are also in clinical development. The durability of
responses to immune checkpoint inhibitors is not yet
well established, and close monitoring for signs/
symptoms of paraneoplastic syndromes and autoim-
mune disease is necessary. Current and future trialsutilizing immune checkpoint inhibitors and other
modulators of the immune response will further
explore clinical activity, biomarkers, toxicities, and the
role of combination strategies in SCLC.Using stem cell biology to design
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Stem cell biology is integral to understanding the
development and treatment responses of lung cancers.
Our laboratories used ideas from stem cell biology to
explore one of the ﬁrst genetic mouse models of the
lung squamous cell carcinoma, driven by conditional
bialleleic inactivation of Stk11 (Lkb1) and Pten in the
murine lung. Cells that could serially transplant disease
(i.e. cancer stem cells) expressed markers of basal cells,
the upper airway stem cells, and highly expressed the
immune evasion molecule PD-L1. This was in contrast
to the lung adenocarcinoma stem cells from the Kras/
p53 mouse model that rely upon other pathways and
share characteristics of distal lung stem cells. Since
anti-PD1 blockade has shown promise in treating lung
squamous cell carcinomas, we are now exploring if
anti-PD1 targets cancer stem cells, and if so, in what
genotypes and contexts. We have also used ideas from
stem cell biology to build a rationale for combining
epigenetic therapies with common chemotherapies. It
is often found that cancer stem cells are resistant to
chemotherapy, and combination of chemotherapies
with targeted therapies could improve treatment out-
comes. Expression of the histone methyltransferase
EZH2 in lung tumors is correlated with a poor survival
of lung cancer patients, and is therefore an attractive
targeted therapy candidate. Because EZH2 is highly co-
expressed with the Topoisomerase II (TopoII) gene
TOP2A in lung cancers, we examined whether EZH2
inhibition synergized with the common chemotherapy
etoposide, which targets TopoII. We found that lung
cancers with activating mutations in EGFR, or with
inactivating mutations in the BAF complex member
BRG1, were both sensitized to etoposide by EZH2 in-
hibition. We are now exploring the mechanism through
which BRG1 loss of function lung cancers, which
represent up to 40% of lung adenocarcinomas, are
speciﬁcally sensitized to etoposide by EZH2 inhibition.
